Guidance for clinical trials that use Decentralised Manufactured Investigational Medicinal Products (IMPs).
Similar Posts
Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47
Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.
Device specific vigilance guidance: Coronary Stents and associated delivery systems
Guidance for manufacturers of coronary stents. It outlines specific scenarios that should be considered when determining if an incident is reportable.
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2025-26
MHRA transactions over £500 made using the government procurement card (GPC).
MHRA begins recruitment for new digital roles at Leeds hub to drive innovation and smarter regulation
New jobs to strengthen innovation, safety and smarter regulation across the UK health and life sciences sector.
Guidance: Early Access to Medicines Scheme: Overview
The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions early access to medicines that show early signs of having a major advantage over existing therapeutics.
Professor Alastair Denniston: The future regulation of AI in healthcare
Creating a framework that is safe, fast and trusted.